CGTBioSenic halts ALLOB developmentBioSenic SA has suspended its Phase II proof-of-concept trial on fracture healing with its allogeneic cell therapy ALLOB. more ➔
M&ANeogap fully takes over TCER Oncology shar...Swedish personalised immunotherapy specialist Neogap Therapeutics AB has acquired the remaining shares of its subsidiary, TCER Oncology AB through two new shareholders. more ➔
InfectionAntibody provides broad protection vs hant...An international research team headed by Pablo Guardado-Calvo at Institut Pasteur Paris has demonstrated evaluated antibody efficacy against lethal hantaviruses. more ➔
Spin-outSyncona launches new gene therapy company...Syncona Ltd had spun-out the ophtalmology specialist Beacon Therapeutics Holdings Ltd with a £96m Series A financing. more ➔
AntibodyRoche to file MAA for eculizumab competito...Roche AG has announced positive results from the non-blinded Phase III COMMODORE 1 and 2 trials at the EHA Hybrid Congress in Frankfurt, Germany. more ➔
CGT CGT Catapult expanding with Scotch facilit...The world 3rd largest gene and cell therapy (CGT) cluster, the UK CGT Catapult has expanded its operations opening a subsidiary in Edinburgh. more ➔
CGTBayer AG is joining forces with Acuitas Th...Bayer boosts its gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics Inc. more ➔
financingCytovation ASA raises US$8m in Series ABergen-based Cytovation ASA has raised US$8m in a Series A extension round to push its cancer compound CyPep-1 into Phase II clinical testing. more ➔ , more ➔
The innovative power of the chemical indus... The Chemspec Europe 2023 provided insights into current challenges of the chemical industry, as well as the solutions it holds. more ➔
autoimmunityStem cell gene transfer treats IL-1 immune...Italian researchers have successfully ameliorated several IL-1-based autoimmune disorders by gene therapy into transplantable hematopoietic stem cells of mice. more ➔
